Related Experiment Video
Updated: Nov 15, 2025

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
Published on: May 24, 2024
The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant
Douglas N VanDerwerken1, Nicholas L Wood1, Dorry L Segev2,3,4
1Department of MathematicsUS Naval AcademyAnnapolisMD.
Background And Aims:
Scores from the Model for End-Stage Liver Disease (MELD), which are used to prioritize candidates for deceased donor livers, are widely acknowledged to be negatively correlated with the 90-day survival rate without a liver transplant. However, inconsistent and outdated estimates of survival probabilities by MELD preclude useful applications of the MELD score.
Approach And Results:
Using data from all prevalent liver waitlist candidates from 2016 to 2019, we estimated 3-day, 7-day, 14-day, 30-day, and 90-day without-transplant survival probabilities (with confidence intervals) for each MELD score and status 1A. We used an adjusted Kaplan-Meier model to avoid unrealistic assumptions and multiple observations per person instead of just the observation at listing. We found that 90-day without-transplant survival has improved over the last decade, with survival rates increasing >10% (in absolute terms) for some MELD scores. We demonstrated that MELD correctly prioritizes candidates in terms of without-transplant survival probability but that status 1A candidates' short-term without-transplant survival is higher than that of MELD 40 candidates and lower than that of MELD 39 candidates. Our primary result is the updated survival functions themselves.
Conclusions:
We calculated without-transplant survival probabilities for each MELD score (and status 1A). The survival function is an invaluable tool for many applications in liver transplantation: awarding of exception points, calculating the relative demand for deceased donor livers in different geographic areas, calibrating the pediatric end-stage liver disease score, and deciding whether to accept an offered liver.
Insights
Updated survival estimates for the Model for End-Stage Liver Disease (MELD) score show improved 90-day survival rates for liver transplant candidates. These refined MELD survival probabilities enhance organ allocation and clinical decision-making.
Area of Science:
- Hepatology
- Transplant Surgery
- Biostatistics
Background:
- The Model for End-Stage Liver Disease (MELD) score is crucial for prioritizing liver transplant candidates.
- Current MELD survival probability estimates are outdated, limiting their clinical utility.
- Accurate survival data is essential for effective liver allocation and patient management.
Purpose of the Study:
- To provide updated, precise 3-day to 90-day survival probabilities for liver transplant candidates across the MELD score spectrum.
- To assess the impact of MELD score and Status 1A on short-term survival.
- To generate reliable survival functions for improved liver allocation and decision-making.
Main Methods:
- Utilized data from prevalent liver waitlist candidates (2016-2019).
- Employed an adjusted Kaplan-Meier model for survival probability estimation.
- Calculated survival probabilities for each MELD score and Status 1A.
Main Results:
- Demonstrated a significant improvement in 90-day post-transplant survival over the past decade.
- Confirmed MELD score accurately reflects survival probability, with notable differences for Status 1A patients.
- Generated updated survival functions for MELD scores and Status 1A.
Conclusions:
- Updated survival probabilities enhance the utility of the MELD score in liver transplantation.
- These refined estimates support critical applications like exception point awards and geographic demand calculations.
- The generated survival functions are invaluable for optimizing liver allocation and clinical decisions.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

